Senescence is a double-edged sword in cancer therapy, capable of driving tumor-promoting and tumor-suppressive responses. In this issue of Nature Aging, González-Gualda, Reinius and colleagues identify activation of TGFβ signaling as the key protumorigenic activity and a viable therapeutic target within the senescence program triggered by platinum-based chemotherapy in ovarian and lung cancers.
- Saima Hassan
- Gerardo Ferbeyre